|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension显示文摘INTRODUCTIONAngiogenesisorformationofnewbloodvesels,isatightlyregulatedprocesinwhichbloodveselssupplygrowingtisuewithnutrient... | Nimer Assy 1,4 , M Paizi 3,4 , D Gaitini 2, Y Baruch 1,4 and G Spira 3,4,5 | 1999 | World Journal of Gastroenterology1999，5，4： | 35 |
| 2 | Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-nave patients显示文摘AIM: To determine whether adding vitamin D, a potent immunomodulator, improves the hepatitis C virus (HCV) response to antiviral therapy. METHODS: Seventy-two consecutive patients with chronic HCV genotype 1 were randomized into two groups: the treatment group (n = 36, 50% male, mean age 47 ± 11 years) received Peg-α-2b interferon (1.5 μg/kg per week) plus ribavirin (1000-1200 mg/d) together with vitamin D3 (2000 IU/d, target serum level > 32 ng/mL), and the control group (n = 36, 60% male, mean age 49 ± 7 years) received identical therapy without vitamin D. HCV-RNA was assessed by realtime polymerase chain reaction (sensitivity, 10 IU/mL). The sustained virologic response (SVR) was defined as undetectable HCV-RNA at 24 wk post-treatment. RESULTS: Clinical characteristics were similar in both groups. The treatment group had a higher mean bodymass index (27 ± 4 kg/m2 vs 24 ± 3 kg/m2, P < 0.01), viral load (50% vs 42%, P < 0.01), and fibrosis score (> F2: 42% vs 19%, P < 0.001) than the controls. At week 4, 16 (44%) treated patients and 6 (17%) controls were HCV-RNA negative (P < 0.001). At week 12, 34 (94%) treated patients and 17 (48%) controls were HCV-RNA negative (P < 0.001). At 24 wk post-treatment (SVR), 31 (86%) treated patients and 15 (42%) controls were HCV-RNA negative (P < 0.001). Viral load, advanced fibrosis and vitamin D supplementation were strongly and independently associated with SVR (multivariate analysis). Adverse events were mild and typical of Peg-α-2b/ribavirin. CONCLUSION: Adding vitamin D to conventional Peg-α-2b/ribavirin therapy for treatment-na■ve patients with chronic HCV genotype 1 infection significantly improves the viral response. | Saif Abu-Mouch Zvi Fireman Jacob Jarchovsky Abdel-Rauf Zeina Nimer Assy Liver Unit | 2011 | World Journal of Gastroenterology2011，17，47： | 29 |
| 3 | Vitamin D improves viral response in hepatitis C genotype 2-3 nave patients显示文摘AIM: To examine whether vitamin D improved viral response and predicted treatment outcome in patients with hepatitis C virus (HCV) genotype 2-3. METHODS: Fifty patients with chronic HCV genotype 2-3 were randomized consecutively into two groups: Treatment group [20 subjects, age 48 ± 14 years, body mass index (BMI) 30 ± 6, 65% male], who received 180 μg pegylated α-interferon-2a plus oral ribavirin 800 mg/d (Peg/RBV), together with oral vitamin D3 (Vitamidyne D drops; 2000 IU/d, 10 drops/d, normal serum level > 32 ng/mL) for 24 wk; and control group (30 subjects, age 45 ± 10 years, BMI 26 ± 3, 60% male), who received identical therapy without vitamin D. HCV RNA was assessed by reverse transcription polymerase chain reaction. Undetectable HCV RNA at 4, 12 and 24 wk after treatment was considered as rapid virological response, complete early virological response, and sustained virological response (SVR), respectively. Biomarkers of in? ammation were measured. RESULTS: The treatment group with vitamin D hadhigher BMI (30 ± 6 vs 26 ± 3, P < 0.02), and high viral load (> 400 000 IU/mL, 65% vs 40%, P < 0.01) than controls. Ninety-fi ve percent of treated patients were HCV RNA negative at week 4 and 12. At 24 wk after treatment (SVR), 19/20 (95%) treated patients and 23/30 (77%) controls were HCV RNA negative (P < 0.001). Baseline serum vitamin D levels were lower at baseline (20 ± 8 ng/mL) and increased after 12 wk vitamin D treatment, to a mean level of (34 ± 11 ng/ mL). Logistic regression analysis identifi ed vitamin D supplement [odds ratio (OR) 3.0, 95% CI 2.0-4.9, P < 0.001], serum vitamin D levels (< 15 or > 15 ng/mL, OR 2.2, P < 0.01), and BMI (< 30 or > 30, OR 2.6, P < 0.01) as independent predictors of viral response. Adverse events were mild and typical of Peg/RBV. CONCLUSION: Low vitamin D levels predicts negative treatment outcome, and adding vitamin D to conventional Peg/RBV therapy for patients with HCV genotype 2-3 signifi cantly improves viral response. | Assy Nimer Abu Mouch | 2012 | World Journal of Gastroenterology2012，18，8： | 24 |
| 4 | Olive oil consumption and non-alcoholic fatty liver disease显示文摘The clinical implications of non-alcoholic fatty liver diseases(NAFLD)derive from their potential to progress to fibrosis and cirrhosis.Inappropriate dietary fat intake,excessive intake of soft drinks,insulin resistance and increased oxidative stress results in increased free fatty acid delivery to the liver and increased hepatic triglyceride(TG)accumulation.An olive oil-rich diet decreases accumulation of TGs in the liver,improves postprandial TGs,glucose and glucagonlike peptide-1 responses in insulin-resistant subjects, and upregulates glucose transporter-2 expression in the liver.The principal mechanisms include:decreased nuclear factor-kappaB activation,decreased lowdensity lipoprotein oxidation,and improved insulin resistance by reduced production of inflammatory cytokines(tumor necrosis factor,interleukin-6)and improvement of jun N-terminal kinase-mediated phosphorylation of insulin receptor substrate-1.The beneficial effect of the Mediterranean diet is derived from monounsaturated fatty acids,mainly from olive oil.In this review,we describe the dietary sources of the monounsaturated fatty acids,the composition of olive oil,dietary fats and their relationship to insulin resistance and postprandial lipid and glucose responses in non-alcoholic steatohepatitis,clinical and experimental studies that assess the relationship between olive oil and NAFLD,and the mechanism by which olive oil ameliorates fatty liver,and we discuss future perspectives. | Nimer Assy Faris Nassar Gattas Nasser Maria Grosovski | 2009 | World Journal of Gastroenterology2009，15，15： | 22 |
| 5 | Soft drinks consumption and nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease(NAFLD) is a common clinical condition which is associated with metabolic syndrome in 70% of cases.Inappropriate dietary fat intake,excessive intake of soft drinks,insulin resistance and increased oxidative stress combine to increase free fatty acid delivery to the liver,and increased hepatic triglyceride accumulation contributes to fatty liver.Regular soft drinks have high fructose corn syrup which contains basic sugar building blocks,fructose 55% and glucose 45%.Soft drinks are the leading source of added sugar worldwide,and have been linked to obesity,diabetes,and metabolic syndrome.The consumption of soft drinks can increase the prevalence of NAFLD independently of metabolic syndrome.During regular soft drinks consumption,fat accumulates in the liver by the primary effect of fructose which increases lipogenesis,and in the case of diet soft drinks,by the additional contribution of aspartame sweetener and caramel colorant which are rich in advanced glycation end products that potentially increase insulin resistance and inflammation.This review emphasizes some hard facts about soft drinks,reviews fructose metabolism,and explains how fructose contributes to the development of obesity,diabetes,metabolic syndrome,and NAFLD. | William Nseir Fares Nassar Nimer Assy | 2010 | World Journal of Gastroenterology2010，16，21： | 20 |
| 6 | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease显示文摘瞄准:估计是否有在有 ezetimibe 和 valsartan 的联合的敏化胰岛素的代理人(ISA ) 的治疗在胆碱缺乏的食谱(MCDD ) 老鼠非酒精的脂肝疾病(NAFLD ) 建模的蛋氨酸与单音的治疗相比每氧化在肝的胖内容和类脂化合物上有更大的效果。方法:老鼠( n = 6 每组)与不同的药被对待,仅仅包括 MCDD ,有任何一个 metformin ( 200 mg/kg )的 MCDD 饮食, rosiglitazone ( 3 mg/kg ),加 rosiglitazone ( M+R )的 metformin , ezetimibe ( 2 mg/kg ), valsartan ( 2 mg/kg ),或为 15 wk 的一个总数的所有药的联合。肝组织学,类脂化合物,氧化应力和 TNF-alpha 的参数被测量。结果:脂肝( FL )老鼠表明了严重肝的脂肪浸润(>
91%脂肪),随肝的 TG 的增加(+1263%, P <
0.001 ),肝的胆固醇(+245%, P <
0.03 ),肝的 MDA 层次(+225%, P <
0.001 ),浆液 TNF-alpha ( 17.8 +/- 10 对 7.8 +/- 0.0 , P <
0.001 ),但是在肝的高山的减少哈生育酚(-74%, P<0.001 )作为与控制老鼠相比。有所有药的联合治疗在肝脂肪变性生产了重要减少(-54%), 肝的 TG (-64%), 肝的胆固醇(-31%) 和肝的 MDA (-70%), 但是增加的肝的高山哈生育酚(+443%) 同样与 FL 老鼠相比。有 ISA 的联合治疗独自在肝脂肪变性生产了更小的减少(-32% 对 -54%, P <
0.001 ) 并且在肝的 MDA 层次(-55% 对 -70%, P <
0.01 ) ,但是在肝的类脂化合物的类似的减少什么时候与相比所有药联合。除了在 ISA 组, TNF-alpha 层次在所有处理组显著地减少了。结论:联合治疗在与单音的治疗相比同样满意的肝脂肪上有更大的效果。Rosiglitazone 看起来比 metformin 在很大程度上改进肝的脂肪变性。 | Nimer Assy Masha Grozovski Ilana Bersudsky Sergio Szvalb Osamah Hussein | 2006 | World Journal of Gastroenterology2006，12，27： | 15 |
| 7 | Role of diet and lifestyle changes in nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease(NAFLD)has becomeone of the most common causes of liver disease worldwide and has been recognized as a major health burden.The prevalence of NAFLD has grown proportionallywith the rise in obesity,sedentary lifestyle,unhealthydietary pattern,and metabolic syndrome.Currently,there is no drug therapy that can be formulated fortreating NAFLD.A combination of dietary modificationsand increased physical activity remains the mainstayof NAFLD management.It is hard to maintain thismode of management;however,it seems to havesignificant long-term benefits.Furthermore,NAFLDpatients,whether obese or not,should be educatedthat a healthy diet and physical activity have benefitsbeyond weight reduction.Further large controlled randomized trials are needed in order to identify the bestdietary regimen and physical activity in the management of NAFLD patients.This review highlights the roleof diet and lifestyle modifications in the managementof NAFLD,and focuses on human studies regarding dietary modifications and physical activity. | William Nseir Elias Hellou Nimer Assy | 2014 | World Journal of Gastroenterology2014，20，28： | 9 |
| 8 | Characteristics of common solid liver lesions and recommendations for diagnostic workup显示文摘Due to the widespread clinical use of imaging modalities such as ultrasonography,computed tomography and magnetic resonance imaging (MRI),previously unsuspected liver masses are increasingly being found in asymptomatic patients.This review discusses the various characteristics of the most common solid liver lesions and recommends a practical approach for diagnostic workup.Likely diagnoses include hepatocellular carcinoma (the most likely;a solid liver lesion in a cirrhotic liver) and hemangioma (generally presenting as a mass in a non-cirrhotic liver).Focal nodular hyperplasia and hepatic adenoma should be ruled out in young women.In 70% of cases,MRI with gadolinium differentiates between these lesions.Fine needle core biopsy or aspiration,or both,might be required in doubtful cases.If uncertainty persists as to the nature of the lesion,surgical resection is recommended.If the patient is known to have a primary malignancy and the lesion was found at tumor staging or follow up,histology is required only when the nature of the liver lesion is doubtful. | Nimer Assy Gattas Nasser Agness Djibre Zaza Beniashvili Saad Elias Jamal Zidan | 2009 | World Journal of Gastroenterology2009，15，26： | 9 |
| 9 | Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification显示文摘AIM:To compare noninvasive methods presently used for steatosis detection and quantification in nonalcoholic fatty liver disease(NAFLD).METHODS:Cross-sectional study of subjects from the general population,a subgroup from the First Israeli National Health Survey,without excessive alcohol consumption or viral hepatitis.All subjects underwent anthropometric measurements and fasting blood tests.Evaluation of liver fat was performed using four noninvasive methods:the SteatoTest;the fatty liver index(FLI);regular abdominal ultrasound(AUS);and the hepatorenal ultrasound index(HRI).Two of the noninvasive methods have been validated vs liver biopsy and were considered as the reference methods:the HRI,the ratio between the median brightness level of the liver and right kidney cortex;and the SteatoTest,a biochemical surrogate marker of liver steatosis.The FLI is calculated by an algorithm based on triglycerides,body mass index,γ-glutamyl-transpeptidase and waist circumference,that has been validated only vs AUS.FLI < 30 rules out and FLI ≥ 60 rules in fatty liver.RESULTS:Three hundred and thirty-eight volunteers met the inclusion and exclusion criteria and had valid tests.The prevalence rate of NAFLD was 31.1% according to AUS.The FLI was very strongly correlated with SteatoTest(r = 0.91,P < 0.001) and to a lesser but significant degree with HRI(r = 0.55,P < 0.001).HRI and SteatoTest were significantly correlated(r = 0.52,P < 0.001).The κ between diagnosis of fatty liver by SteatoTest(≥ S2) and by FLI(≥ 60) was 0.74,which represented good agreement.The sensitivity of FLI vs SteatoTest was 85.5%,specificity 92.6%,positive predictive value(PPV) 74.7%,and negative predictive value(NPV) 96.1%.Most subjects(84.2%) with FLI < 60 had S0 and none had S3-S4.The κ between diagnosis of fatty liver by HRI(≥ 1.5) and by FLI(≥ 60) was 0.43,which represented only moderate agreement.The sensitivity of FLI vs HRI was 56.3%,specificity 86.5%,PPV 57.0%,and NPV 86.1%.The diagnostic accuracy of FLI for steatosis > 5%,as predicted by SteatoTest,yielded an area under the receiver operating characteristic curve(AUROC) of 0.97(95% CI:0.95-0.98).The diagnostic accuracy of FLI for steatosis> 5%,as predicted by HRI,yielded an AUROC of 0.82(95% CI:0.77-0.87).The κ between diagnosis of fatty liver by AUS and by FLI(≥ 60) was 0.48 for the entire sample.However,after exclusion of all subjects with an intermediate FLI score of 30-60,the κ between diagnosis of fatty liver by AUS and by FLI either ≥ 60 or < 30 was 0.65,representing good agreement.Excluding all the subjects with an intermediate FLI score,the sensitivity of FLI was 80.3% and the specificity 87.3%.Only 8.5% of those with FLI < 30 had fatty liver on AUS,but 27.8% of those with FLI ≥ 60 had normal liver on AUS.CONCLUSION:FLI has striking agreement with SteatoTest and moderate agreements with AUS or HRI.However,if intermediate values are excluded FLI has high diagnostic value vs AUS. | Shira Zelber-Sagi Muriel Webb Nimer Assy Laurie Blendis Hanny Yeshua Moshe Leshno Vlad Ratziu Zamir Halpern Ran Oren Erwin Santo | 2013 | World Journal of Gastroenterology2013，19，1： | 8 |
| 10 | Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg(-) chronic hepatitis B patients from inactive chronic carriers显示文摘AIM:To determine whether new cut-off values for alanine aminotransferase(ALT)and baseline hepatitis B virus(HBV)DNA levels better differentiate HBeAg(-) chronic hepatitis B(CHB)patients from inactive chronic carriers. METHODS:Ninety-one patients[32 HBeAg(+)CHB, 19 inactive carriers and 40 HBeAg(-)CHB]were followed up for 2 years and were tested for HBV DNA levels by a PCR-based assay.ALT was tested twice during the last 6 mo using new cut-off values:ULN(upper limit of normal)30 IU/L for males,19 IU/L for females. Diagnostic accuracy,sensitivity,specificity,positive and negative predictive values were calculated by discriminant analysis. RESULTS:When using the revised ALT cut-off values, the lowest optimal HBV DNA level that differentiated HBeAg(-)CHB patients from inactive carriers was 50000 copies/mL.The diagnostic accuracy of HBV DNA to determine inactive carriers with a cut-off of 50000 copies/mL was similar to the previously recommended cut-off of 100 000 copies/mL(91%).HBV DNA levels were lower than the cut-off value in 95%of inactive carriers and in 28%of HBeAg(-)CHB patients.With ALT<30 IU/L in men and<19 IU/L in women and HBV DNA levels<100 000 copies/mL,the risk of CHB is 5%.On the other hand,if ALT values were>30 IU in men and>19 IU in women and baseline HBV DNA levels were>100000 copies/mL,the risk is 86%. CONCLUSION:New cut-off values for ALT together with HBV DNA levels proposed by AASLD(American Association for the Study of Liver Diseases)and NIH (National Institute of Health)consensus seem appropriate to characterize inactive carriers. | Nimer Assy Zaza Beniashvili Agness Djibre Gattas Nasser Maria Grosovski William Nseir | 2009 | World Journal of Gastroenterology2009，15，24： | 7 |
| 11 | Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients显示文摘AIM To describe the relationships between non-alcoholic fatty-liver disease(NAFLD) patient's disease consequences and treatment perceptions, self-efficacy, and healthy lifestyle maintenance. METHODS A cross-sectional study among 146 ultrasound diagnosed NAFLD patients who visited the fatty liver clinic at the TelAviv Medical Center. Eighty-seven of these individuals, participated in a clinical trial of physical activity and underwent fasting blood tests, analyzed at the same lab. Exclusion criteria included positivity for serum HBsA g or anti-HCV antibodies; fatty liver suspected to be secondary to hepatotoxic drugs; excessive alcohol consumption(≥ 30 g/d in men or ≥ 20 g/d in women) and positive markers of genetic or immune-mediated liver diseases. Patients were asked to complete a selfreport structured questionnaire, assembled by the Israeli Center for Disease Control. Nutrition habits were measured using six yes/no questions(0 = no, 1 = yes) adopted from the national survey questionnaire. Participants in the clinical trial completed a detailed semi-quantitative food frequency questionnaire(FFQ) reporting their habitual nutritional intake during the past year. Self-efficacy was assessed by the Self-Efficacy Scale questionnaire, emotional representation, degree of illness understanding, timeline perception, treatment perception and symptoms were measured by the Brief Illness Perception questionnaire. Illness consequences were measured by the Personal Models of Diabetes Interview questionnaire. A path analysis was performed to describe the interrelationships between the patients' illness perceptions, and assess the extent to which the data fit a prediction of nutritional habits.RESULTS The study sample included 54.1% men, with a mean age of 47.76 ± 11.68 years(range: 20-60) and mean body mass index of 31.56 ± 4.6. The average perceived nutrition habits score was 4.73 ± 1.45 on a scale between 0-6, where 6 represents the healthiest eating habits. Most of the study participants(57.2%) did not feel they fully understood what NAFLD is. Better nutritional habits were positively predicted by the degree of illness understanding(β = 0.26; P = 0.002) and selfefficacy(β = 0.25; P = 0.003). Perceptions of more severe illness consequences were related with higher emotional representation(β = 0.55; P < 0.001), which was related with lower self-efficacy(β =-0.17; P = 0.034). The perception of treatment effectiveness was positively related with self-efficacy(β = 0.32; P < 0.001). In accordance with the correlation between self-efficacy and the perceived nutrition habits score, self-efficacy was also correlated with nutrient intake evaluated by the FFQ; negatively with saturated fat(percent of saturated fat calories from total calories)(r =-0.28, P = 0.010) and positively with fiber(r = 0.22, P = 0.047) and vitamin C intake(r = 0.34, P = 0.002). In a sub analysis of the clinical trial participants, objectively measured compliance to physical activity regimen was positively correlated with the self-efficacy level(r = 0.34, P = 0.046). CONCLUSION Self-efficacy and illness understanding are major determinants of lifestyle-modification among NAFLD patients. This information can assist clinicians in improving compliance with lifestyle changes among these patients. | Shira Zelber-Sagi Shiran Bord Gali Dror-Lavi Matthew Lee Smith Samuel D Towne Jr Assaf Buch Muriel Webb Hanny Yeshua Assy Nimer Oren Shibolet | 2017 | World Journal of Gastroenterology2017，23，10： | 6 |
| 12 | Predicting common bile duct stones by non-invasive parameters显示文摘Background:Common bile duct(CBD)stone affect about 10%of patients with symptomatic cholelithiasis.The American Society for Gastrointestinal Endoscopy(ASGE)published a strategy in 2010 for managing patients with suspected choledocholithiasis.This study aimed to assess the performance of different clinical parameters in predicting CBD stones.Methods:A total of 344 patients suspected to suffer from CBD stone and referred to endoscopic ultrasound(EUS)were included.Parameters were collected and their prediction power for CBD stones was assessed.Results:One hundred and sixty-seven patients without CBD stone according to EUS(group A)were compared to 177 patients with CBD stones(group B).Several predictive factors for CBD stone were identified on univariate analysis.In multivariate regression analysis,CBD width by US(OR=1.224,95%CI:1.073–1.359;P=0.0026),age(OR=1.023,95%CI:1.011–1.035;P=0.0002)and gamma glutamyl transferase(GGT)level(OR=1.001,95%CI:1.000–1.002;P=0.0018)were significantly correlated with CBD stone,with receiver operator characteristics(ROC)of 0.7259.We generated a diagnostic equation[age(yr)×0.1+CBD width(mm)by US×1+GGT(U/L)×0.005]to predict CBD stone with ROC of 0.7287.Conclusions:We suggest this score as a very strong predictor for CBD stones,and to reduce the strength of total bilirubin and transaminases as predictors. | Anas Kadah Tawfik Khoury Mahmud Mahamid Nimer Assy Wisam Sbeit | 2020 | Hepatobiliary & Pancreatic Diseases International2020，19，3： | 4 |
| 13 | Nutritional recommendations for patients with non-alcoholic fatty liver diseases显示文摘Fatty liver is the most common liver disease worldwide.Patients with fatty liver disease die primarily from cardiovascular disease and not from chronic liver diseases.Hyperglycemia and hyperinsulinemia induce lipogenesis,thereby increasing the hepatic pool of fatty acids.This pool is also increased by increased delivery of fatty acids through the diet or lipolysis in adipose tissue.Nutritional consultations and lifestyle modification are important in the treatment of non-alcoholic fatty liver disease(NAFLD).Among the dietary constituents,combination of vitamin D,vitamin E,and omega-3 fatty acids shows promise for the treatment of NAFLD. | Nimer Assy | 2011 | World Journal of Gastroenterology2011，17，29： | 4 |
| 14 | Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats显示文摘AIM: To evaluate the effects of different types of dietary fats on the hepatic lipid content and oxidative stress parameters in rat liver with experimental non-alcoholic fatty liver disease (NAFLD). METHODS: A total of 32 Sprague-Dawley rats were randomly divided into fi ve groups. The rats in the control group (n = 8) were on chow diet (Group 1), rats (n = 6) on methionine choline-defi cient diet (MCDD) (Group 2), rats (n = 6) on MCDD enriched with olive oil (Group 3), rats (n = 6) on MCDD with fish oil (Group 4) and rats (n = 6) on MCDD with butter fat (Group 5). After 2 mo, blood and liver sections were examined for lipids composition and oxidative stress parameters.RESULTS: The liver weight/rat weight ratio increased in all treatment groups as compared with the control group. Severe fatty liver was seen in MCDD + fish oil and in MCDD + butter fat groups, but not in MCDD and MCDD + olive oil groups. The increase in hepatic triglycerides (TG) levels was blunted by 30% in MCDD + olive oil group (0.59 ± 0.09) compared with MCDD group (0.85 ± 0.04, P < 0.004), by 37% compared with MCDD + fi sh oil group (0.95 ± 0.07, P < 0.001), and by 33% compared with MCDD + butter group (0.09 ± 0.1, P < 0.01). The increase in serum TG was lowered by 10% in MCDD + olive oil group (0.9 ± 0.07) compared with MCDD group (1.05 ± 0.06). Hepatic cholesterol increased by 15-fold in MCDD group [(0.08 ± 0.02, this increment was blunted by 21% in MCDD + f ish oil group (0.09 ± 0.02)]. In comparison with the control group, ratio of long-chain polyunsaturated fatty acids omega-6/ | Osamah Hussein Masha Grosovski Etti Lasri Sergio Svalb Uzi Ravid Nimer Assy | 2007 | World Journal of Gastroenterology2007，13，3： | 3 |
| 15 | Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine(5hmC)显示文摘As a dioxygenase, Ten-Eleven Translocation 2(TET2) catalyzes subsequent steps of 5-methylcytosine(5 mC) oxidation. TET2 plays a critical role in the self-renewal, proliferation,and differentiation of hematopoietic stem cells, but its impact on mature hematopoietic cells is not well-characterized. Here we show that Tet2 plays an essential role in osteoclastogenesis. Deletion of Tet2 impairs the differentiation of osteoclast precursor cells(macrophages) and their maturation into bone-resorbing osteoclasts in vitro. Furthermore, Tet2^(-/-) mice exhibit mild osteopetrosis, accompanied by decreased number of osteoclasts in vivo. Tet2 loss in macrophages results in the altered expression of a set of genes implicated in osteoclast differentiation, such as Cebpa, Mafb, and Nfkbiz. Tet2 deletion also leads to a genome-wide alteration in the level of 5-hydroxymethylcytosine(5 hmC) and altered expression of a specific subset of macrophage genes associated with osteoclast differentiation. Furthermore, Tet2 interacts with Runx1 and negatively modulates its transcriptional activity. Our studies demonstrate a novel molecular mechanism controlling osteoclast differentiation and function by Tet2, that is, through interactions with Runx1 and the maintenance of genomic 5 hmC. Targeting Tet2 and its pathway could be a potential therapeutic strategy for the prevention and treatment of abnormal bone mass caused by the deregulation of osteoclast activities. | Yajing Chu Zhigang Zhao David Wayne Sant Ganqian Zhu Sarah M. Greenblatt Lin Liu Jinhuan Wang Zeng Cao Jeanette Cheng Tho Shi Chen Xiaochen Liu Peng Zhang Jaroslaw P. Maciejewski Stephen Nimer Gaofeng Wang Weiping Yuan Feng-Chun Yang Mingjiang Xu | 2018 | Genomics, Proteomics & Bioinformatics2018，16，3： | 2 |
| 16 | Non-imaging-guided fine-needle aspiration of liver lesions:aretrospective study of 279 patients显示文摘RESULTSBasedonhistologic,cytologicandclinicalfindings,finalliverdiagnoseswerereachedin265patients,ofwhom171hadmalignantand94... | Yeouda Edoute 1,4 , Ehud Malberger 2,4 , Orly Tibon Fisher 2 and Nimer Assy 3,4 | 1999 | World Journal of Gastroenterology1999，5，2： | 2 |
| 17 | Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid显示文摘 | Nimer Assy Paul C. Adams Paul Myers Verra Simon Gerry Y. Minuk William Wall Cameron N. Ghent | 2007 | Transplantation2007，，12： | 2 |
| 18 | Clinical management of myelodysplasticsyndromes with interstitial deletion of chromosome 5q显示文摘 | NIMER S D | 2006 | J Clin Oncol2006，24，： | 1 |
| 19 | Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma显示文摘 | Kewalramani T Zelenetz AD Nimer SD | 2004 | Blood2004，103，10： | 1 |
| 20 | Gm-csf rescues tf-1 cellsfrom growth factor withdrawal-induced, but not differentia-tion-induced apoptosis: the role of bcl-2 and mcl-l显示文摘 | Klampfer L Zhang J Nimer S D | 1999 | Cyto-kine1999，11，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员